Stockreport

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sutro Biopharma, Inc.  (STRO) 
Last sutro biopharma, inc. earnings: 11/8 07:00 am Check Earnings Report
PDF - 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in pa [Read more]